Elizabeth Bailey, PA
Medical · Portland, MENPI 1215004809
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Takeda Pharmaceuticals U.S.A., Inc. accounts for 65.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $17,194 and has fallen 91.2% since, to $1,519 in 2025. Among medical clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $71.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Gilead$1K
- Boston Scientific$953
- Johnson & Johnson$568
- plus $2K from 19 others
What the payments were for
- Consulting fees$5502%
- Speaking & faculty fees$10,26042%
- Travel & lodging$4,93120%
- Food & beverage$8,65935%
- Education$1461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $16,150 |
| AbbVie | 91 | $2,163 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 67 | $1,506 |
| Gilead | 33 | $1,095 |
| Boston Scientific | 6 | $953 |
| Johnson & Johnson(2 entities) | 18 | $568 |
| Madrigal Pharmaceuticals | 12 | $486 |
| Intercept Pharmaceuticals, Inc. | 5 | $304 |
| Regeneron Healthcare Solutions, Inc. | 8 | $173 |
| Bristol Myers Squibb | 5 | $172 |
| Pfizer | 7 | $148 |
| Janssen Scientific Affairs, LLC | 2 | $141 |
| Apollo Endosurgery US Inc | 1 | $134 |
| Sanofi | 2 | $129 |
| Novo Nordisk | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 1 | $66 |
| Lilly USA, LLC | 3 | $63 |
| Celltrion USA Inc. | 2 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Exact Sciences | 1 | $24 |
| Ardelyx, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $17 |
| Sandoz | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,546 in reported general payments places this provider in the 95th percentile of 67 medical providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 27 | $722,200 |
| Humira(Cf) PenAdalimumab | 19 | $145,705 |
| OcalivaObeticholic Acid | 13 | $114,728 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 12 | $77,653 |
| CreonLipase/Protease/Amylase | 28 | $59,364 |
| XifaxanRifaximin | 18 | $48,834 |
| Mesalamine | 38 | $22,590 |
| VemlidyTenofovir Alafenamide | 12 | $18,889 |
| MotegrityPrucalopride Succinate | 26 | $16,693 |
| LinzessLinaclotide | 15 | $8,939 |
| Ursodiol | 11 | $3,104 |
| Mesalamine ErMesalamine | 13 | $2,156 |
| Colestipol Hcl | 37 | $2,124 |
| Pantoprazole Sodium | 65 | $1,288 |
| Rabeprazole Sodium | 13 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $568 | $722,20027 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $304 | $114,72813 claims |
| AbbVieCreon, Linzess | $2,163 | $68,30343 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,506 | $48,83418 claims |
| GileadVemlidy | $1,095 | $18,88912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $16,150 | $16,69326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 medical providers in Maine.
Other medical in Portland
- Ishah FowlerPortland$991
- Emily AkleyPortland$732
- Michael GagePortland$400
- Mark MorrisPortland$306
- Elizabeth EvansPortland$73
- Elaine CadoretteScarborough$8K
- Bethany GatesAugusta$6K
- Lindy ThomasBangor$4K
- Lisa BoucherAuburn$3K
- Alan ColmanBangor$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.